JP2023505206A5 - - Google Patents

Info

Publication number
JP2023505206A5
JP2023505206A5 JP2022533373A JP2022533373A JP2023505206A5 JP 2023505206 A5 JP2023505206 A5 JP 2023505206A5 JP 2022533373 A JP2022533373 A JP 2022533373A JP 2022533373 A JP2022533373 A JP 2022533373A JP 2023505206 A5 JP2023505206 A5 JP 2023505206A5
Authority
JP
Japan
Prior art keywords
cells
derived
immune cells
receptor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505206A (ja
JP7879804B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063457 external-priority patent/WO2021113744A1/en
Publication of JP2023505206A publication Critical patent/JP2023505206A/ja
Publication of JP2023505206A5 publication Critical patent/JP2023505206A5/ja
Application granted granted Critical
Publication of JP7879804B2 publication Critical patent/JP7879804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533373A 2019-12-06 2020-12-04 小化合物を使用するiPSC由来エフェクター免疫細胞の増強 Active JP7879804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945040P 2019-12-06 2019-12-06
US62/945,040 2019-12-06
PCT/US2020/063457 WO2021113744A1 (en) 2019-12-06 2020-12-04 Enhancement of ipsc-derived effector immune cell using small compounds

Publications (3)

Publication Number Publication Date
JP2023505206A JP2023505206A (ja) 2023-02-08
JP2023505206A5 true JP2023505206A5 (cg-RX-API-DMAC7.html) 2023-12-11
JP7879804B2 JP7879804B2 (ja) 2026-06-24

Family

ID=76221001

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533373A Active JP7879804B2 (ja) 2019-12-06 2020-12-04 小化合物を使用するiPSC由来エフェクター免疫細胞の増強

Country Status (11)

Country Link
US (1) US20230016034A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069827A4 (cg-RX-API-DMAC7.html)
JP (1) JP7879804B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220124179A (cg-RX-API-DMAC7.html)
CN (1) CN115087731A (cg-RX-API-DMAC7.html)
AU (1) AU2020395239A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011072A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160423A1 (cg-RX-API-DMAC7.html)
IL (1) IL293564A (cg-RX-API-DMAC7.html)
MX (1) MX2022006725A (cg-RX-API-DMAC7.html)
WO (1) WO2021113744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2022011065A1 (en) * 2020-07-07 2022-01-13 The Nemours Foundation Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer
US20220387488A1 (en) * 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
WO2022269393A1 (en) * 2021-06-23 2022-12-29 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
US20240307540A1 (en) * 2021-07-02 2024-09-19 Fate Therapeutics, Inc. Protected effector cells and use thereof for allogeneic adoptive cell therapies
US20250018034A1 (en) * 2021-11-08 2025-01-16 Fate Therapeutics, Inc. Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors
TW202340453A (zh) * 2022-01-28 2023-10-16 中國大陸商杭州啟函生物科技有限公司 用於基於細胞的免疫療法的方法和組合物
KR20250005097A (ko) * 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
WO2024097911A1 (en) * 2022-11-02 2024-05-10 Fate Therapeutics, Inc. Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d
WO2024102704A2 (en) * 2022-11-07 2024-05-16 Fate Therapeutics, Inc. Ipsc-derived nk cell targeting mica/b for solid tumor treatment
WO2025104248A1 (en) * 2023-11-17 2025-05-22 Repairon Immuno Gmbh Method of producing an immune cell devoid of endogenous effector functions from pluripotent stem cells
CN117305241B (zh) * 2023-11-28 2024-03-19 上海兴瑞一达生物科技有限公司 一种hiPSCs诱导分化为NK细胞的方法
WO2025217183A1 (en) * 2024-04-09 2025-10-16 Board Of Regents, The University Of Texas System Prepared natural killer cells and uses thereof
CN119220607B (zh) * 2024-12-03 2025-03-07 星奕昂(上海)生物科技有限公司 编辑tim3基因获得功能强化的car-nk细胞的方法与应用
CN121472143B (zh) * 2026-01-06 2026-03-31 南京医拓生物科技有限公司 高活化状态nk细胞富集型淋巴细胞的培养方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US12642852B1 (en) * 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
JP7653759B2 (ja) * 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
JP6727334B2 (ja) * 2016-02-01 2020-07-22 グリーン・クロス・ラブ・セル・コーポレイション 細胞の凍結保存のための培地組成物およびその使用
PL3618842T3 (pl) * 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
US12036241B2 (en) * 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
EP3822342A4 (en) * 2018-07-13 2022-08-03 Kyoto University METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS

Similar Documents

Publication Publication Date Title
JP2022541441A5 (cg-RX-API-DMAC7.html)
JP2022550899A5 (cg-RX-API-DMAC7.html)
JP2022548943A5 (cg-RX-API-DMAC7.html)
US12448445B2 (en) Transgene genetic tags and methods of use
JP2022510207A5 (cg-RX-API-DMAC7.html)
JP2021505131A5 (cg-RX-API-DMAC7.html)
KR102618231B1 (ko) 변형된 만능성 줄기 세포, 및 제조 및 사용 방법
JP2023548467A5 (cg-RX-API-DMAC7.html)
JP2023530704A5 (cg-RX-API-DMAC7.html)
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
JP2023549098A5 (cg-RX-API-DMAC7.html)
US11458168B2 (en) NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
CA3107675A1 (en) Improving the efficacy and safety of adoptive cellular therapies
JP2021519061A5 (cg-RX-API-DMAC7.html)
JP2023548829A5 (cg-RX-API-DMAC7.html)
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
KR20180021137A (ko) 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법
JP2024502157A (ja) 樹状細胞活性化キメラ抗原受容体及びその使用
JP2023029624A (ja) strepタグ特異的キメラ受容体およびその使用
JP2023545992A5 (cg-RX-API-DMAC7.html)
JP2024515920A5 (cg-RX-API-DMAC7.html)
EP3805366A1 (en) Improved t-cell therapy method
JP7701453B2 (ja) 固形腫瘍標的化骨格を有する細胞及びその使用
JP2025105605A5 (cg-RX-API-DMAC7.html)
JP2024526237A5 (cg-RX-API-DMAC7.html)